Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gavestinel SCHEMBL30184856 | 1.00 | GPR17 (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL678632 | 1.00 | GPR17 (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995817 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995813 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995818 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8344945 | 0.91 | GPR17 (0.84) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL9014837 | 0.90 | KDM4E (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1720490 | 0.90 | KDM4E (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9395908 | 0.88 | GPR17 (0.79) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9395914 | 0.88 | GPR17 (0.79) | GPR17MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407454-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2012-01-18 | — | — | EP | claimed |
| US-20110319463-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AS ACTIVE INGREDIENTS | Saten Pharamaceuticals Co., Ltd. (JP) | 2011-12-29 | — | — | US | claimed |
| US-6020359-A | INJECTABLE SOLUTION OF 3-(2-(PHENYLCARBAMOYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOXYLIC ACID; GLYCINE ANTAGONIST | GLAXO WELLCOME SPA (IT) | 2000-02-01 | — | — | US | claimed |
| US-5886018-A | COMPRISING A SOLUTION OF A GLYCINE ANTAGONIST WHICH IS (E)-3-(2-(PHENYLCARBAMOYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOX YLIC ACID OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF IN AN ISOTONIC SUGAR SOLUTION CONTAINING A WATER MISCIBLE SOLVENT | GLAXO WELLCOME SPA (IT) | 1999-03-23 | — | — | US | claimed |
| EP-0809514-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.p.A. (IT) | 1997-12-03 | — | — | EP | claimed |
| WO-1996024376-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.P.A. (IT) | 1996-08-15 | — | — | WO | claimed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-8741955-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735451-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-2407454-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-5886018-A | COMPRISING A SOLUTION OF A GLYCINE ANTAGONIST WHICH IS (E)-3-(2-(PHENYLCARBAMOYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOX YLIC ACID OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF IN AN ISOTONIC SUGAR SOLUTION CONTAINING A WATER MISCIBLE SOLVENT | GLAXO WELLCOME SPA (IT) | 1999-03-23 | — | — | US | disclosed |
| US-5886018-A | COMPRISING A SOLUTION OF A GLYCINE ANTAGONIST WHICH IS (E)-3-(2-(PHENYLCARBAMOYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOX YLIC ACID OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF IN AN ISOTONIC SUGAR SOLUTION CONTAINING A WATER MISCIBLE SOLVENT | GLAXO WELLCOME SPA (IT) | 1999-03-23 | — | — | US | disclosed |
| EP-0809514-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.p.A. (IT) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996024376-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.P.A. (IT) | 1996-08-15 | — | — | WO | disclosed |
| US-5510367-A | TREATMENT OR PREVENTION OF NEUROTOXIC INJURIES SUCH AS CEREBRAL STROKE, HEMMORHAGIC STROKE, CEREBRAL ISCHEMIA, VASOSPASM, HYPOGLYCEMIA, ANAESIA, HYPOXIA, ASHYXIA, CARDIAC ARREST AND NEURODEGENERATIVE DISEASES | GLAXO SPA (IT) | 1996-04-23 | — | — | US | disclosed |
| US-5373018-A | Antagonist to excitory amino acids on N-methyl aspartic acid receptor complex, theraputically effective in treatment of central nervous system disorder | GLAXO S.P.A. (IT) | 1994-12-13 | — | — | US | disclosed |
| EP-0568136-A1 | Indole-2-carboxylic acid derivatives | GLAXO S.p.A. (IT) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319463-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AS ACTIVE INGREDIENTS | ALDH1A2, NEFM, QDPR | GPR17 3295/4885MEN1 2599/4885KMT2A 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.